Ambey Laboratories Limited (NSE:AMBEY)
India
· Delayed Price · Currency is INR 21.50
-1.50 (-6.52%)
At close: Mar 9, 2026
Ambey Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 |
| Operating Revenue | 1,318 | 1,313 | 1,205 | 1,048 | 846.01 | 817.39 | Upgrade
|
| Other Revenue | 9.9 | 16.31 | 14.6 | 26.57 | 3.04 | 3.83 | Upgrade
|
| Revenue | 1,328 | 1,329 | 1,219 | 1,075 | 849.05 | 821.23 | Upgrade
|
| Revenue Growth (YoY) | 2.27% | 9.00% | 13.45% | 26.59% | 3.39% | 22.50% | Upgrade
|
| Cost of Revenue | 1,174 | 1,172 | 1,068 | 909.12 | 688.97 | 663.54 | Upgrade
|
| Gross Profit | 153.83 | 157.28 | 150.97 | 165.66 | 160.08 | 157.69 | Upgrade
|
| Selling, General & Admin | 29.16 | 28.7 | 28.08 | 35.61 | 29.98 | 27.9 | Upgrade
|
| Other Operating Expenses | 18.23 | 16.42 | 17.57 | 25.27 | 23.65 | 26.69 | Upgrade
|
| Operating Expenses | 71.83 | 70.55 | 70.8 | 90.5 | 83.33 | 86.81 | Upgrade
|
| Operating Income | 82.01 | 86.72 | 80.17 | 75.16 | 76.75 | 70.88 | Upgrade
|
| Interest Expense | -29.04 | -27.68 | -23.1 | -19.46 | -30.51 | -40.95 | Upgrade
|
| Interest & Investment Income | 1.5 | 1.5 | 0.1 | 0.06 | 0.06 | 0.4 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.24 | 0.24 | 1.16 | 1.03 | 2.02 | 0.55 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.43 | -1.43 | -1.04 | -1.15 | - | -0 | Upgrade
|
| EBT Excluding Unusual Items | 53.27 | 59.35 | 57.28 | 55.64 | 48.31 | 30.88 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.11 | 1.11 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.07 | -0.07 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | -2.97 | -0.61 | - | - | Upgrade
|
| Pretax Income | 54.31 | 60.38 | 54.32 | 55.03 | 48.31 | 30.88 | Upgrade
|
| Income Tax Expense | 9.93 | 12.56 | -22.9 | 2.63 | 12.56 | -72.48 | Upgrade
|
| Net Income | 44.37 | 47.83 | 77.22 | 52.4 | 35.75 | 103.37 | Upgrade
|
| Net Income to Common | 44.37 | 47.83 | 77.22 | 52.4 | 35.75 | 103.37 | Upgrade
|
| Net Income Growth | -5.82% | -38.06% | 47.36% | 46.59% | -65.42% | 4684.68% | Upgrade
|
| Shares Outstanding (Basic) | 25 | 23 | 18 | 18 | 5 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 25 | 23 | 18 | 18 | 5 | 5 | Upgrade
|
| Shares Change (YoY) | - | 27.87% | 2.44% | 251.74% | 3.12% | - | Upgrade
|
| EPS (Basic) | 1.78 | 2.06 | 4.25 | 2.95 | 7.08 | 21.12 | Upgrade
|
| EPS (Diluted) | 1.78 | 2.06 | 4.25 | 2.95 | 7.08 | 21.12 | Upgrade
|
| EPS Growth | - | -51.56% | 43.96% | -58.36% | -66.46% | 4689.87% | Upgrade
|
| Free Cash Flow | -640.52 | -480.01 | -182.57 | 69.61 | 48.48 | 15.36 | Upgrade
|
| Free Cash Flow Per Share | -25.67 | -20.65 | -10.04 | 3.92 | 9.61 | 3.14 | Upgrade
|
| Gross Margin | 11.58% | 11.83% | 12.38% | 15.41% | 18.85% | 19.20% | Upgrade
|
| Operating Margin | 6.18% | 6.53% | 6.58% | 6.99% | 9.04% | 8.63% | Upgrade
|
| Profit Margin | 3.34% | 3.60% | 6.33% | 4.88% | 4.21% | 12.59% | Upgrade
|
| Free Cash Flow Margin | -48.24% | -36.12% | -14.97% | 6.48% | 5.71% | 1.87% | Upgrade
|
| EBITDA | 104.62 | 110.33 | 102.92 | 102.34 | 103.45 | 98.68 | Upgrade
|
| EBITDA Margin | 7.88% | 8.30% | 8.44% | 9.52% | 12.18% | 12.02% | Upgrade
|
| D&A For EBITDA | 22.62 | 23.61 | 22.75 | 27.19 | 26.7 | 27.8 | Upgrade
|
| EBIT | 82.01 | 86.72 | 80.17 | 75.16 | 76.75 | 70.88 | Upgrade
|
| EBIT Margin | 6.18% | 6.53% | 6.58% | 6.99% | 9.04% | 8.63% | Upgrade
|
| Effective Tax Rate | 18.29% | 20.79% | - | 4.77% | 26.00% | - | Upgrade
|
| Revenue as Reported | 1,331 | 1,332 | 1,221 | 1,076 | 851.12 | 824.15 | Upgrade
|
| Advertising Expenses | - | 1.04 | 1.44 | 2.87 | 2.13 | 1.31 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.